- •Metabolic surgery is associated with lower risk of developing obesity-associated cancer.
- •Metabolic surgery is associated with lower risk of cancer-related mortality.
- •There is a dose-dependent response between weight loss and cancer risk: the greater the weight loss, the lower the risk of cancer.
- •Available data suggest substantial weight loss (over 20-25%) is necessary to significantly reduce cancer risk in people with obesity.
Obesity incidence continues to rise globally along with obesity-associated conditions, which heavily burden individuals’ quality of life and healthcare systems. Evidence regarding the power of metabolic and bariatric surgery to treat obesity has, fortunately, brought to light how substantial and sustained weight loss can mitigate adverse clinical outcomes of obesity and metabolic disease. Obesity-associated cancer has been an important focus of studies in recent decades to further elucidate what impact metabolic surgery could have on incidence of cancer and cancer-related mortality. The SPLENDID (Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death) study is one of the recent large cohort studies that highlights the power of substantial weight loss and the long-term benefits to patients with obesity in preventing cancer. This review of SPLENDID aims to highlight both consistency of results with prior studies and new findings unexplored previously.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery for Obesity and Related Diseases
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Association of bariatric surgery with cancer risk and mortality in adults with obesity.JAMA. 2022; 327: 2423-2433
- Obesity surgery and risk of cancer.Br J Surg. 2018; 105: 1650-1657
- Bariatric surgery and the risk of cancer in a large multisite cohort.Ann Surg. 2019; 269: 95-101
- Cancer incidence and mortality after gastric bypass surgery.Obesity (Silver Spring). 2009; 17: 796-802
- Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial.Lancet Oncol. 2009; 10: 653-662
- Body fatness and cancer--viewpoint of the IARC Working Group.N Engl J Med. 2016; 375: 794-798
- IFSO Worldwide Survey 2016: primary, endoluminal, and revisional procedures.Obes Surg. 2018; 28: 3783-3794
- Cancer risk after bariatric surgery in a cohort study from the five Nordic countries.Obes Surg. 2020; 30: 3761-3767
- Cardiovascular outcomes in patients with type 2 diabetes and obesity: comparison of gastric bypass, sleeve gastrectomy, and usual care.Diabetes Care. 2021; 44: 2552-2563
- Development of cancer after bariatric surgery.Surg Obes Relat Dis. 2020; 16: 1586-1595
- weight loss strategies for treatment of obesity: lifestyle management and pharmacotherapy.Prog Cardiovasc Dis. 2018; 61: 246-252
- Management of obesity.Lancet. 2016; 387: 1947-1956
- Tirzepatide once weekly for the treatment of obesity.N Engl J Med. 2022; 387: 205-216
- Once-weekly semaglutide in adults with overweight or obesity.N Engl J Med. 2021; 384: 989-1002
- Weight and metabolic outcomes 12 years after gastric bypass.N Engl J Med. 2017; 377: 1143-1155
- Bariatric surgery versus conventional medical therapy for type 2 diabetes.. 2012; 366: 1577-1585
- Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity.JAMA. 2019; 322: 1271-1282
- Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis.JAMA. 2021; 326: 2031-2042
- Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the look AHEAD randomized clinical trial.Obesity (Silver Spring). 2020; 28: 1678-1686
- Association between weight loss and serum biomarkers with risk of incident cancer in the Longitudinal Assessment of Bariatric Surgery cohort.Surg Obes Relat Dis. 2020; 16: 1086-1094
- Association of bariatric surgery with cancer risk and mortality—reply.JAMA. 2022; 328: 1646
- The role of mendelian randomization studies in deciphering the effect of obesity on cancer.J Natl Cancer Inst. 2022; 114: 361-371
- Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070.Nat Rev Clin Oncol. 2021; 18: 663-672
- American Cancer Society guideline for diet and physical activity for cancer prevention.CA Cancer J Clin. 2020; 70: 245-271
Published online: February 06, 2023
Accepted: January 29, 2023
Received: January 24, 2023
Publication stageIn Press Journal Pre-Proof
© 2023 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.